B-Cell Directed Therapies for Autoimmune Diseases is a conference dedicated to the next generation of B and plasma cell directed therapies.
B-Cell Directed Therapies for Autoimmune Diseases covers topics such as:
- Translational approaches and considerations for clinical trial design and patient stratification with Novartis and University of Rochester
- Fundamental B and plasma cell biology to identify pathogenic subtypes and therapeutic targets with Duke University, Universities of Texas and Colorado
- Small molecule inhibitor approaches that impact B cell function in autoimmunity with Incyte, Biogen and Principia Biopharma
- The latest approaches targeting T & B cell crosstalk through T cell dependent mechanisms with AnTolRx, Akston Biosciences and Cour Pharmaceuticals
- Next generation biologics approaches targeting pathogenic B cells with Jounce Therapeutics and Momenta Pharmaceuticals
